Abuse liability assessment of sibutramine, a novel weight control agent

Psychopharmacology

Volumn 147, Issue 4, 2000, Pages 339-346

  Schuh, Leslie M ^a   Schuster, Charles R ^a   Hopper, John A ^a   Mendel, Carl M ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Abuse potential; d Amphetamine; Human; Sibutramine; Subjective effect

Indexed keywords

DEXAMPHETAMINE; PLACEBO; SIBUTRAMINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEMALE; HUMAN; MALE; MOOD; OBESITY; PRIORITY JOURNAL; REINFORCEMENT; WEIGHT REDUCTION;

EID: 0033984025     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050001     Document Type: Article

References (22)

1. Balcioglu A, Wurtman RJ (1998) Dexfenfluramine enhances striatal dopamine release in conscious rats via a serotonergic mechanism. J Pharmacol Exp Ther 284:991-997
2. Bray GA, Blackburn GL, Ferguson, JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB (1999) Sibutramine produces dose-related weight loss. Obesity Res 7:189-198
3. Buckett WR, Thomas PC, Luscombe GP (1988) The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry 12:575-584
4. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML (1998) Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Pharmacol 18:231-236
5. Fischman MW, Mello NK (1989) Testing for abuse liability of drugs in humans. NIDA Research Monograph No. 92, US DHHS Publication No. (ADM) 89-1613
6. Gosden J, Heal DJ (1998) Evaluation of sibutramine, its active metabolites and dexfenfluramine in the MDMA-cued drug discrimination test. Int J Obesity 22:S122 (Abstract #P94)
7. Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993) Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4:3-13
8. Gundlah C, Martin KF, Heal DJ, Auerbach SB (1997) In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 283:581-590
9. Haertzen CA (1974) An overview of Addiction Research Center Inventory Scales (ARCI): an appendix and manual of scales. US Government Printing Office, Washington, D.C., pp 74-92
10. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P (1998) Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obesity 22:32-38
11. Heal DJ, Frankland AT, Buckett WR (1990) A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain. Neuropharmacology 29:1141-1150
12. Heal DJ, Frankland ATJ, Gosden J, Hutchins LJ, Prow MR, Luscombe GP, Buckett WR (1992) A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology 107:303-309
13. Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR (1998) A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 125:301-308
14. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR (1989) The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by putative antidepressant sibutramine hydrochloride. Neuropharmacology 28:129-134
15. McNair DM, Lorr M, Droppleman LF (1971) BITS manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego, Calif.
16. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiological, subjective and behavioral effects of d-amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258
17. Moore KE (1977) The actions of amphetamine on neurotransmitters: a brief review. Biol Psychiatry 12:451-462
18. Prow MR, Aspley S, Butler S, Broughton D, Martin KF, Heal DJ (1997) Hallucinogenic abuse liability of sibutramine, its active metabolites and reference drugs measured by their ability to induce head-twitches in mice. Proceedings of the NAASO Annual Conference, Mexico, November
19. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS (1998) Sibutramine reduces food intake in non-dieting women with obesity. Obesity Res 6:1-11
20. Samanin R, Garattini S (1993) Neurochemical mechanisms of anorectic drugs. Pharmacol Toxicol 73:63-68
21. Seagle HM. Bessesen DH, Hill JO (1998) Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obesity Res 6:115-121
22. Yamamoto T, Ueki S (1981) The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs. Pharmacol Biochem Behav 14:89-95